Why Ligand (LGND) Could Be an Impressive Growth Stock
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is Ligand Pharmaceuticals Inc. LGND. This firm, which is in the biomedical and genetics industry, saw EPS growth of 51.6% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 76.1%. Furthermore, the long-term growth rate is currently an impressive 25% suggesting pretty good prospects for the long haul.
Ligand Pharmaceuticals Incorporated Price and Consensus
Ligand Pharmaceuticals Incorporated Price and Consensus | Ligand Pharmaceuticals Incorporated Quote
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 14.4%. Thanks to this rise in earnings estimates, LGND has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank stocks here.
So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider LGND. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for LGND as well.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
